Author: Ohadian Moghadam, Solmaz
Title: A Review on Currently Available Potential Therapeutic Options for COVID-19 Cord-id: s66r5n3f Document date: 2020_7_24
ID: s66r5n3f
Snippet: A series of unexplained pneumonia cases currently were first reported in December 2019 in Wuhan, China. Official names have been announced for the virus responsible, previously known as “2019 novel coronavirus†and the diseases it causes are, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease (COVID-19), respectively. Despite great efforts worldwide to control SARS-CoV-2, the spread of the virus has reached a pandemic. Infection prevention and control of thi
Document: A series of unexplained pneumonia cases currently were first reported in December 2019 in Wuhan, China. Official names have been announced for the virus responsible, previously known as “2019 novel coronavirus†and the diseases it causes are, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease (COVID-19), respectively. Despite great efforts worldwide to control SARS-CoV-2, the spread of the virus has reached a pandemic. Infection prevention and control of this virus is the primary concern of public health officials and professionals. Currently, several therapeutic options for COVID-19 are proposed and vaccine development has been initiated for prevention purposes. In this review, we will discuss the most recent evidence about the current potential treatment options including anti-inflammatory drugs, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, nucleoside analogs, protease inhibitors, monoclonal antibodies, and convalescent plasma therapy. Some other agents such as vitamin D and melatonin, which were recommended as potential adjuvant treatments for COVID-19 infection are also presented. Moreover, the potential use of convalescent plasma for treatment of COVID-19 infection was described. Furthermore, in the next part of the current review, various vaccination approaches against COVID-19 including whole virus vaccines, recombinant subunit vaccine, DNA vaccines, and mRNA vaccines are discussed.
Search related documents:
Co phrase search for related documents- ace inhibitor and acute ards respiratory distress syndrome: 1, 2, 3, 4
- ace inhibitor and acute phase: 1
- ace inhibitor and acute respiratory failure: 1
- ace inhibitor and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- ace rbd binding and acute ards respiratory distress syndrome: 1
- ace rbd binding and acute respiratory syndrome: 1, 2, 3, 4, 5, 6
- acei angiotensin converting enzyme inhibitor and acute ards respiratory distress syndrome: 1
- acei angiotensin converting enzyme inhibitor and acute respiratory failure: 1, 2, 3
- acei angiotensin converting enzyme inhibitor and acute respiratory syndrome: 1, 2, 3, 4, 5
- activator kinase signal transducer and acute respiratory failure: 1
- activator kinase signal transducer and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9
- activator kinase signal transducer and adaptive immune response: 1
- active component and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8
- active infection and acute ards respiratory distress syndrome: 1, 2, 3, 4
- active infection and acute phase: 1, 2, 3, 4, 5, 6, 7
- active infection and acute respiratory failure: 1, 2, 3, 4, 5
- active infection and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- active infection and adaptive immune response: 1, 2, 3, 4, 5
- active infection and adaptive immune system: 1
Co phrase search for related documents, hyperlinks ordered by date